Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.3
Journals
JCM
Special Issues
Exploring Diagnostic and Therapeutic Advances in Neurodegenerative Disorders
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Exploring Diagnostic and Therapeutic Advances in Neurodegenerative Disorders

A Special Issue of Journal of Clinical Medicine (ISSN 2077-0383) belonging to the section "Clinical Neurology".

Deadline for manuscript submissions: 20 March 2027 | Viewed by 930

Editors

Dr. Stefania Kalampokini

E-Mail Website
Guest Editor
First Department of Neurology, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece
Interests: clinical neurology; neurobiology; brain physiology; neurodegenerative diseases; movement disorders; behavioral psychology; adult neurology; neuroinflammation; multiple sclerosis; neuropsychology; emotion recognition
Special Issues, Collections and Topics in MDPI journals
Dr. Effrosyni Koutsouraki

E-Mail Website
Guest Editor
First Department of Neurology, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece
Interests: multiple sclerosis; cognitive disorders in multiple sclerosis; dementia; mild cognitive impairment; Alzheimer disease; neurocognitive disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Neurodegenerative disorders are a major concern for clinicians and especially neurologists. Our understanding of the mechanisms, pathophysiology, and therapeutic potential of these diseases is steadily increasing. This Special Issue focuses on tools that can be implemented in new diagnostic and therapeutic, including artificial intelligence, novel imaging methods, and biomarkers. The Special Issue will cover topics such as Parkinson’s disease, Alzheimer’s disease, Lewy body dementia, and Huntington’s disease, as well as topics such as immunosenescence, i.e., the abnormal activation or dysfunction of the immune system as people age, and inflammaging, i.e., a chronic, low-grade inflammatory state associated with immunosenescence, which is thought to be associated with neurodegenerative disorders. The Special Issue aims to integrate current knowledge on the clinical management of patients with degenerative diseases.

Dr. Stefania Kalampokini
Dr. Effrosyni Koutsouraki
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegenerative disease
  • Parkinson’s disease
  • Alzheimer’s disease
  • Friedreich’s ataxia
  • Huntington’s disease
  • Lewy body dementia
  • dementia
  • immunosenescence
  • inflammaging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

31 pages, 5918 KB  
Review
Anti-Amyloid Antibodies in the Treatment of Alzheimer’s Disease: An Umbrella Review
by Stefania Kalampokini, Iraklis Keramidiotis, Antonis Frontistis, Francesca Zuchi, Dimitrios Michmizos, Vasileios Papaliagkas and Effrosyni Koutsouraki
J. Clin. Med. 2026, 15(17), 6782; https://doi.org/10.3390/jcm15176782 - 1 Sep 2026
Viewed by 509
Abstract
Background: Over the last decade, numerous studies have investigated the administration of monoclonal anti-amyloid antibodies (AAAs) as a therapeutic approach in Alzheimer’s disease (AD). The purpose of this umbrella review is to summarize current knowledge concerning the efficacy and safety of FDA- and [...] Read more.
Background: Over the last decade, numerous studies have investigated the administration of monoclonal anti-amyloid antibodies (AAAs) as a therapeutic approach in Alzheimer’s disease (AD). The purpose of this umbrella review is to summarize current knowledge concerning the efficacy and safety of FDA- and EMA-approved AAAs for AD, namely, lecanemab and donanemab. Methods: We conducted a literature search in the PubMed, Scopus, and Web of Science databases in English, focusing on systematic reviews and/or meta-analyses, assessed by AMSTAR 2, concerning clinical and imaging efficacy, i.e., cognitive improvement and reduction of beta-amyloid on PET scan, as well as safety, i.e., adverse events and amyloid-related imaging abnormalities (ARIA). The extracted review-level dataset was entered into SPSS Version 26 for descriptive statistical analysis. Results: This umbrella review included 11 systematic reviews and/or meta-analyses. Patients treated with lecanemab or donanemab showed statistically significant changes on cognitive scales such as the Clinical Dementia Rating-Sum of Boxes (CDR-SB) (mean effect estimate −0.485, SD = 0.152, −0.70 to −0.34) and the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), but most were below or around clinically meaningful thresholds. Lecanemab and donanemab showed a statistically significant decrease in amyloid PET outcomes, including centiloids or the standardized uptake value ratio. Both antibodies were linked to ARIA, including amyloid-related imaging abnormalities-edema (ARIA-E OR 8.32–12.26) and amyloid-related imaging abnormalities-hemorrhage (ARIA-H OR 2–5.77), especially in ApoEε4 carriers. Conclusions: Lecanemab and donanemab are biologically active drugs for the treatment of early AD, with cognitive benefits below or around the clinically meaningful threshold. They are, however, associated with increased ARIA risk. Their administration depends upon careful patient selection, shared decision-making, and clear communication regarding expectations. Full article
(This article belongs to the Special Issue Exploring Diagnostic and Therapeutic Advances in Neurodegenerative Disorders)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop